Tzu‐Hsiu Tsai

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

Chia‐Chi Lin, Jin‐Yuan Shih, Chong‐Jen Yu et al. · The Lancet Respiratory Medicine · 2017 · 144 citations

Medicine, Genetics, Oncology +16

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors

Ching‐Yao Yang, Wei‐Yu Liao, Chao‐Chi Ho et al. · European Journal of Cancer · 2019 · 91 citations

Medicine, Immunology, Oncology +17

IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer

Yinan Liu, Tzu‐Hua Chang, Meng‐Feng Tsai et al. · Oncotarget · 2015 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Yen‐Fu Chen, Min‐Shu Hsieh, Shang‐Gin Wu et al. · Journal of Thoracic Oncology · 2014 · 82 citations

Medicine, Genetics, Oncology +17

Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer

Yi‐Nan Liu, Meng‐Feng Tsai, Shang‐Gin Wu et al. · International Journal of Cancer · 2019 · 62 citations · Full text

Medicine, Oncology, Pharmacology +16